Surface Plasmon Resonance Identifies High-Affinity Binding of l-DOPA to Siderocalin/Lipocalin-2 through Iron-Siderophore Action: Implications for Parkinson's Disease Treatment

Multicolorimetric Sensor Array Based on Silver Metallization of Gold Nanorods for Discriminating Dopaminergic Agents

Dopaminergic agents are compounds that modulate dopamine-related activity in the brain and peripheral nerves within the pathways on both sides of the blood-brain barrier. Atypical levels of them can precipitate a multitude of neurological disorders, whose timely diagnosis signifies not only stopping the advancement of the illness but also surmounting it. A silver metallized gold nanorod (AuNRs) conditional sensor array, designed to detect dopaminergic agents for assessing nervous system disorders, yielded significant results in simultaneous detection and discrimination of Benserazide (Benz), Levodopa (L-DOPA), and Carbidopa (Carb). The array was composed of two different concentrations of silver ions as sensor elements (SEs), which generated unique signatures indicative of the presence of reductive target analytes, triggered by the incongruent formation of the Au@Ag core-shell, causing visual and fingerprint colorimetric patterns. Generating diverse responses is the key to the functionality of array-based sensing, which facilitated achieving spectral and color variation originating from the blue shift of AuNRs longitudinal localized surface plasmon resonance (LLSPR) in the extinction spectrum. Also, employing a smartphone camera enables clear visual discrimination across an extensive concentration span. Pattern recognition through linear discriminant analysis (LDA) underscored the robust discrimination accuracies of this sensor, along with quantification by means of partial least-squares regression (PLSR), affirming its potential for practical applications. Notably, the array demonstrated high sensitivity in detecting varied concentrations of target analytes, even in commercial drug samples. The sensor responses exhibited a linear correlation with the concentrations of Benz, L-DOPA, and Carb ranging from 1.59 to 100.0, 5.26 to 100.0, and 5.32 to 100.0 μmol L-1, respectively, and the minimum detectable concentrations for Benz, L-DOPA, and Carb were measured at 0.53, 1.75, and 1.77 μmol L-1, respectively. The implemented machine-learning-empowered array-based sensor represents advancements in dopaminergic agent tracing and naked eye detection.

Neuroprotective effects of brown rice consumption in an iron-induced parkinsonism in Drosophila

OBJECTIVES

Iron (Fe) accumulation and resultant oxidative stress play a significant role in the neuronal death observed in Parkinson's disease (PD). Brown rice (BR) possesses antioxidant properties able to reduce cellular oxidative damage. Thus, we hypothesized that BR may ameliorate Fe-induced parkinsonism due to oxidative stress.

METHODS

Two - to three-day-old male flies were concurrently exposed to Fe (ferrous sulphate, 1 mM) and interventions, divided into eight groups: control; Fe; BR; white rice (WR); L-dopa (1 mM); Fe (1 mM) + BR; Fe (1 mM) + WR; and Fe (1 mM) + L-dopa (1 mM). The flies were exposed for 15 days to their respective diets, and their behavior, relevant biomarkers, and the expression of related genes were evaluated.

RESULTS

Chronic exposure to Fe caused cognitive and locomotor deficits by increasing Fe levels (p = 0.027) in flies' heads, as well as heightened aggression and grooming episodes (p < 0.001). The elevated iron levels induced changes consistent with oxidative stress, evidenced by increased MDA levels (p < 0.001), and reduced activity of catalase (p < 0.001) and glutathione peroxidase (GPx) (p < 0.001), along with decreased dopamine levels (p < 0.001). Additionally, there was dysregulation in the mRNA expression of malvolio, ferritin, Nrf2, DJ-1, GPx, and catalase (p < 0.05). BR prevented the Fe-induced effects (Fe + BR group) even more effectively than L-Dopa (p < 0.001).

CONCLUSION

The findings indicate that BR has the potential to mitigate Fe-induced ROS-mediated damage in a Drosophila model of PD-like disease by modulating key players in the Nrf2 signaling pathway.

Pharmacological Activities and Molecular Mechanisms of Sinapic Acid in Neurological Disorders

Sinapic acid (SA) is a phenylpropanoid derivative found in various natural sources that exhibits remarkable versatile properties, including antioxidant, anti-inflammatory, and metal-chelating capabilities, establishing itself as a promising candidate for the prevention and treatment of conditions affecting the central nervous system, such as Alzheimer's disease (AD), Parkinson's disease (PD), ischemic stroke, and other neurological disorders. These effects also include neuroprotection in epilepsy models, as evidenced by a reduction in seizure-like behavior, cell death in specific hippocampal regions, and lowered neuroinflammatory markers. In AD, SA treatment enhances memory, reverses cognitive deficits, and attenuates astrocyte activation. SA also has positive effects on cognition by improving memory and lowering oxidative stress. This is shown by lower levels of oxidative stress markers, higher levels of antioxidant enzyme activity, and better memory retention. Additionally, in ischemic stroke and PD models, SA provides microglial protection and exerts anti-inflammatory effects. This review emphasizes SA's multifaceted neuroprotective properties and its potential role in the prevention and treatment of various brain disorders. Despite the need for further research to fully understand its mechanisms of action and clinical applicability, SA stands out as a valuable bioactive compound in the ongoing quest to combat neurodegenerative diseases and enhance the quality of life for affected individuals.

Increased plasma lipocalin-2 levels are associated with nonmotor symptoms and neuroimaging features in patients with Parkinson's disease

Lipocalin-2 (LCN2) is essential for the regulation of neuroinflammation and cellular uptake of iron. This study aimed to evaluate plasma LCN2 levels and explore their correlation with clinical and neuroimaging features in Parkinson's disease (PD) patients. Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma LCN2 levels in 120 subjects. Evaluation of motor symptoms and nonmotor symptoms in PD patients was assessed by the associated scales. Voxel-based morphometry (VBM) was used to evaluate brain volume alterations, and quantitative susceptibility mapping (QSM) was used to quantitatively analyze brain iron deposition in 46 PD patients. Plasma LCN2 levels were significantly higher in PD patients than those in healthy controls. LCN2 levels were negatively correlated with Montreal Cognitive Assessment (MoCA) scores, total brain gray matter volume (GMV), and GMV/total intracranial volume (TIV) ratio, but positively correlated with Hamilton Anxiety Rating Scale (HAMD) scores and mean QSM values of the bilateral substantial nigra (SN). Receiver operating characteristic (ROC) curves confirmed that plasma LCN2 levels had good predictive accuracy for PD. The results suggest that plasma LCN2 levels have potential as a biomarker for the diagnosis of PD. LCN2 may be a therapeutic target for neuroinflammation and brain iron deposition.

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non-motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes play a part in the pathogenesis of these fluctuations, a range of barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non-optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, constipation, Helicobacter pylori infection, small intestinal bacterial overgrowth and gut dysbiosis. In addition, a protein-rich diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub-optimal levodopa response, 'delayed on' or 'no on' phenomena. In this narrative review, we provided an overview on the plethora of GI obstacles to levodopa transport and absorption in PD and their implications on levodopa pharmacokinetics and development of motor fluctuations. In addition, management strategies to address GI dysfunction in PD are highlighted, including use of non-oral therapies to bypass the GI tract.

Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease

Background: Increased iron deposition in nigrosome as assessed by susceptibility-weighted imaging (SWI) is involved in the pathogenesis of Parkinson’s disease (PD). This study investigated the effects of antiparkinson drugs on iron deposition in the nigrosome of PD patients.

Methods: Based on the retrospective analysis of clinical data, alterations in iron deposition in the substantia nigra were investigated in 51 PD patients across different types of therapies and in nine Parkinson-plus syndrome patients. The Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part Ⅲ/Ⅳ (UPDRS Ⅲ/Ⅳ) was utilized to evaluate motor function and complications. SWI (slice = 0.6 mm) was used to detect iron deposition in the nigrosome and substantia nigra. Nigrosome loss was scored on a 1-point nigrosome visibility scale. Visual assessment of dorsolateral nigral hyperintensity (DNH) was separately performed for each side of the nigrosome with SWI.

Results: Increased UPDRS Ⅲ scores were correlated with low nigrosome scores based on correlation analysis at a disease duration of 6–12 months (r = −0.8420). The loss of the nigrosome on SWI was clearly inhibited in PD patients with a 3–5-year duration of administration of antiparkinson medications compared with no treatment. Decreased UPDRS Ⅲ scores and increased nigrosome scores were observed in the regular treatment of PD patients with a 6–7-year disease duration. For patients with Parkinson-plus syndromes, such as multiple system atrophy, iron accumulation was apparent in the corpus striatum and substantia nigra compared with that for patients with progressive supranuclear palsy.

Conclusions: Early and regular treatment with antiparkinson drugs not only alleviates the chance of PD disability but also prevents the loss of DNH, namely, iron accumulation in the nigrosome.

Binding of Citrate-Fe3+ to Plastic Culture Dishes, an Artefact Useful as a Simple Technique to Screen for New Iron Chelators

NaCT mediates citrate uptake in the liver cell line HepG2. When these cells were exposed to iron (Fe³⁺), citrate uptake/binding as monitored by the association of [¹⁴C]-citrate with cells increased. However, there was no change in NaCT expression and function, indicating that NaCT was not responsible for this Fe³⁺-induced citrate uptake/binding. Interestingly however, the process exhibited substrate selectivity and saturability as if the process was mediated by a transporter. Notwithstanding these features, subsequent studies demonstrated that the iron-induced citrate uptake/binding did not involve citrate entry into cells; instead, the increase was due to the formation of citrate-Fe³⁺ chelate that adsorbed to the cell surface. Surprisingly, the same phenomenon was observed in culture wells without HepG2 cells, indicating the adsorption of the citrate-Fe³⁺ chelate to the plastic surface of culture wells. We used this interesting phenomenon as a simple screening technique for new iron chelators with the logic that if another iron chelator is present in the assay system, it would compete with citrate for binding to Fe³⁺ and prevent the formation and adsorption of citrate-Fe³⁺ to the culture well. This technique was validated with the known iron chelators deferiprone and deferoxamine, and with the bacterial siderophore 2,3-dihydroxybenzoic acid and the catechol carbidopa.